What is Summit Therapeutics's AFS securities?

Summit Therapeutics (SMMT) reported AFS securities of $0 in Q1 2026.

Summit Therapeutics SMMT AFS Securities

AFS Securities at other companies

BiogenBIIB

$454.7M-32.0%

ModernaMRNA

$2.25B-6.9%

ExelixisEXEL

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's AFS securities?: Summit Therapeutics (SMMT) reported AFS securities of $0 in Q1 2026.